- PR Newswire•11 days ago
NASHVILLE, Tenn., Sept. 14, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), today announced the initiation of a new Phase II clinical program of Portaban™ for patients with portal hypertension associated with liver disease. The U.S. Food and Drug Administration (FDA) has cleared Cumberland's investigational new drug application (IND) for a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study. Portaban™ is an oral formulation of ifetroban and the fourth development candidate in Cumberland's pipeline.
- Capital Cube•17 days ago
Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Cumberland Pharmaceuticals, Inc. Here are 5 ETF’s with the largest exposure to CPIX-US. Comparing the performance and risk of Cumberland Pharmaceuticals, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- PR Newswire•last monthCumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For Oncology Patient Support
NASHVILLE, Tenn., Aug. 23, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing Ethyol® (amifostine) for injection to U.S. wholesalers today. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.
Cumberland Pharmaceuticals, Inc. (CPIX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Ask||12.00 x 300|
|Day's Range||4.97 - 4.97|
|52wk Range||4.20 - 6.50|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-497.00|
|Avg Vol (3m)||12,012|
|Dividend & Yield||N/A (N/A)|